Insulin therapy in people who have dysglycemia and type 2 diabetes mellitus: Can it offer both cardiovascular protection and beta-cell preservation?

Endocrinology and Metabolism Clinics of North America

Volumn 34, Issue 1, 2005, Pages 137-154

  Gerstein, Hertzel C ^a   Rosenstock, Julio ^b,c  

^a MCMASTER UNIVERSITY   (Canada)

^b DALLAS DIABETES AND ENDOCRINE CENTER AT MEDICAL CITY   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLICLAZIDE; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; NATEGLINIDE; PIOGLITAZONE; RAMIPRIL; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; VALSARTAN;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL FUNCTION; CLINICAL TRIAL; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SIDE EFFECT; WEIGHT GAIN;

EID: 14744286020     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2004.11.002     Document Type: Review

References (88)

1. H.C. Gerstein, K. Malmberg, and S. Capes Cardiovascular diseases H.C. Gerstein R.B. Haynes Evidence-based diabetes care 2001 BC Decker Inc. Hamilton (Ontario) 488 514
2. C.C. Cowie, and M.I. Harris Physical and metabolic characteristics of persons with diabetes M.I. Harris C.C. Cowie M.S. Stern Diabetes in America. NIH Publication No. 95-1468 1995 National Institutes of Health Bethesda (MD) 117 164
3. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus Diabetes Care 20 7 1997 1183 1197
4. M. Coutinho, H.C. Gerstein, and Y. Wang The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years Diabetes Care 22 2 1999 233 240
5. DECODE Study Group EDEG Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care 26 3 2003 688 696
6. K.T. Khaw, N. Wareham, and R. Luben Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk) BMJ 322 7277 2001 1 6
7. J.B. Meigs, D.M. Nathan, and R.B. D'Agostino Sr. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study Diabetes Care 25 10 2002 1845 1850
8. I. Kowalska, J. Prokop, and H. Bachorzewska-Gajewska Disturbances of glucose metabolism in men referred for coronary arteriography. Postload glycemia as predictor for coronary atherosclerosis Diabetes Care 24 5 2001 897 901
9. A. Norhammar, A. Tenerz, and G. Nilsson Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study Lancet 359 9324 2002 2140 2144
10. H.C. Gerstein, P. Pais, and J. Pogue Relationship of glucose and insulin levels to the risk of myocardial infarction: a case-control study J Am Coll Cardiol 33 3 1999 612 619
11. S.E. Capes, D. Hunt, and K. Malmberg Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview Lancet 355 9206 2000 773 778
12. K. Foo, J. Cooper, and A. Deaner A single serum glucose measurement predicts adverse outcomes across the whole range of acute coronary syndromes Heart 89 5 2003 512 516
13. J. Sala, R. Masia, and F.J. Gonzalez de Molina Short-term mortality of myocardial infarction patients with diabetes or hyperglycaemia during admission J Epidemiol Community Health 56 9 2002 707 712
14. A.M. Norhammar, L. Ryden, and K. Malmberg Admission plasma glucose. Independent risk factor for long-term prognosis after myocardial infarction even in nondiabetic patients Diabetes Care 22 11 1999 1827 1831
15. C.J. Weir, G.D. Murray, and A.G. Dyker Is hyperglycaemia an independent predictor of poor outcome after acute stroke? Results of a long-term follow up study BMJ 314 7090 1997 1303 1306
16. H.C. Gerstein, and S.E. Capes Dysglycemia: a key cardiovascular risk factor Semin Vasc Med 2 2 2002 165 174
17. S. Genuth, K.G. Alberti, and P. Bennett Follow-up report on the diagnosis of diabetes mellitus Diabetes Care 26 11 2003 3160 3167
18. M.I. Harris, K.M. Flegal, and C.C. Cowie Prevalence of diabetes, impaired fasting glucose and impaired glucose tolerance in US adults. The third National Health and Nutrition Examination Survey, 1988-1994 Diabetes Care 21 4 1998 518 524
19. S. Wild, G. Roglic, and A. Green Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 Diabetes Care 27 5 2004 1047 1053
20. P. Hogan, T. Dall, and P. Nikolov American Diabetes Association. Economic costs of diabetes in the US in 2002 Diabetes Care 26 3 2003 917 932
21. A. Ceriello, and E. Motz Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited Arterioscler Thromb Vasc Biol 24 5 2004 816 823
22. M.P. Stern Diabetes and cardiovascular disease: the "common soil" hypothesis Diabetes 44 4 1995 369 374
23. M. Brownlee Biochemistry and molecular cell biology of diabetic complications Nature 414 6865 2001 813 820
24. R.P. Robertson, J. Harmon, and P.O. Tran Glucose toxicity in beta-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection Diabetes 52 3 2003 581 587
25. UK prospective diabetes study 16 Overview of 6 years' therapy of type II diabetes: a progressive disease. UK Prospective Diabetes Study Group Diabetes 44 11 1995 1249 1258
26. D.M. Nathan, J. Lachin, and P. Cleary Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus N Engl J Med 348 23 2003 2294 2303
27. R.H. Eckel, M. Wassef, and A. Chait Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group II: pathogenesis of atherosclerosis in diabetes Circulation 105 18 2002 e138 e143
28. J.A. Beckman, M.A. Creager, and P. Libby Diabetes and atherosclerosis: epidemiology, pathophysiology, and management JAMA 287 19 2002 2570 2581
29. M. Stumvoll, P.A. Tataranni, and N. Stefan Glucose allostasis Diabetes 52 4 2003 903 909
30. G.F. Lewis, A. Carpentier, and K. Adeli Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes Endocr Rev 23 2 2002 201 229
31. M. Dubois, J. Kerr-Conte, and V. Gmyr Non-esterified fatty acids are deleterious for human pancreatic islet function at physiological glucose concentration Diabetologia 47 3 2004 463 469
32. R. Diaz Metabolic modulation of acute myocardial infarction Crit Care Clin 17 2 2001 469 476
33. A.A. Wolff, H.H. Rotmensch, and W.C. Stanley Metabolic approaches to the treatment of ischemic heart disease: the clinicians' perspective Heart Fail Rev 7 2 2002 187 203
34. G.D. Lopaschuk Metabolic abnormalities in the diabetic heart Heart Fail Rev 7 2 2002 149 159
35. U.N. Das Is insulin an endogenous cardioprotector? Crit Care 6 5 2002 389 393
36. T.K. Hansen, S. Thiel, and P.J. Wouters Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels J Clin Endocrinol Metab 88 3 2003 1082 1088
37. U.N. Das Insulin: an endogenous cardioprotector Curr Opin Crit Care 9 5 2003 375 383
38. S. Vehkavaara, S. Makimattila, and A. Schlenzka Insulin therapy improves endothelial function in type 2 diabetes Arterioscler Thromb Vasc Biol 20 2 2000 545 550
39. T.W. Gress, F.J. Nieto, and E. Shahar Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study N Engl J Med 342 13 2000 905 912
40. G.G. Schwartz, D. Il'yasova, and A. Ivanova Urinary cadmium, impaired fasting glucose, and diabetes in the NHANES III Diabetes Care 26 2 2003 468 470
41. M.P. Longnecker, and J.L. Daniels Environmental contaminants as etiologic factors for diabetes Environ Health Perspect 109 Suppl 6 2001 871 876
42. F.B. Hu, J.E. Manson, and M.J. Stampfer Diet, lifestyle, and the risk of type 2 diabetes mellitus in women N Engl J Med 345 11 2001 790 797
43. Diabetes Prevention Trial-Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus N Engl J Med 346 22 2002 1685 1691
44. Prospective Diabetes Study UK (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 1998 837 853
45. Y. Ohkubo, H. Kishikawa, and E. Araki Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study Diab Res Clin Pract 28 1995 103 117
46. C. Abraira, J.A. Colwell, and F. Nuttall Cardiovascular events and correlates in the veterans affairs diabetes feasibility trial Arch Intern Med 157 1997 181 188
47. S. Genuth Exogenous insulin admininstration and cardiovascular risk in NIDDM and IDDM Ann Intern Med 124 1 pt 2 1996 104 109
48. K. Malmberg Prospective randomised study of intensive insulin treatment on long-term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group BMJ 314 7093 1997 1512 1515
49. C.S. Apstein Increased glycolytic substrate protection improves ischemic cardiac dysfunction and reduces injury Am Heart J 139 2 Pt 3 2000 S107 S114
50. A. Quinones-Galvan, and E. Ferrannini Metabolic effects of glucose-insulin infusions: myocardium and whole body Curr Opin Clin Nutr Metab Care 4 2 2001 157 163
51. M. Lawson, H.C. Gerstein, and E. Tsui Effect of intensive therapy on early macrovascular disease in young individuals with type 1 diabetes. A systematic review and meta-analysis Diabetes Care 22 Suppl.2 1999 B35 B39
52. Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus N Engl J Med 329 1993 977 986
53. Diabetes Control and Complications Trial (DCCT) Research Group Effect of intensive diabetes management on macrovascular events and risk factors in the diabetes control and complications trial Am J Cardiol 75 1995 894 903
54. F. Fath-Ordoubadi, and K.J. Beatt Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials Circulation 96 4 1997 1152 1156
55. R. Diaz, E.A. Paolasso, and L.S. Piegas Metabolic modulation of acute myocardial infarction. The ECLA (Estudios Cardiologicos Latinoamerica) Collaborative Group Circulation 98 21 1998 2227 2234
56. A.P. Furnary, G. Gao, and G.L. Grunkemeier Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting J Thorac Cardiovasc Surg 125 5 2003 1007 1021
57. G. van den Berghe, P. Wouters, and F. Weekers Intensive insulin therapy in critically ill patients N Engl J Med 345 19 2001 1359 1367
58. M.C. Riddle, J. Rosenstock, and J. Gerich The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients Diabetes Care 26 11 2003 3080 3086
59. C. Weyer, C. Bogardus, and D.M. Mott The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus J Clin Invest 104 6 1999 787 794
60. C. Bogardus, and P.A. Tataranni Reduced early insulin secretion in the etiology of type 2 diabetes mellitus in Pima Indians Diabetes 51 Suppl 1 2002 S262 S264
61. R.P. Robertson, J. Harmon, and P.O. Tran Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes Diabetes 53 Suppl 1 2004 S119 S124
62. R.H. Unger Lipotoxic diseases Annu Rev Med 53 2002 319 336
63. G. Leibowitz, M. Yuli, and M.Y. Donath Beta-cell glucotoxicity in the Psammomys obesus model of type 2 diabetes Diabetes 50 Suppl 1 2001 S113 S117
64. J.L. Leahy, S. Bonner-Weir, and G.C. Weir Minimal chronic hyperglycemia is a critical determinant of impaired insulin secretion after an incomplete pancreatectomy J Clin Invest 81 5 1988 1407 1414
65. L. Rossetti, G.I. Shulman, and W. Zawalich Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats J Clin Invest 80 4 1987 1037 1044
66. S. Bonner-Weir, D.F. Trent, and G.C. Weir Partial pancreatectomy in the rat and subsequent defect in glucose-induced insulin release J Clin Invest 71 6 1983 1544 1553
67. J.D. McGarry Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes Diabetes 51 1 2002 7 18
68. Prospective Diabetes Study UK. (UKPDS) Group Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet 352 1998 854 865
69. R.C. Turner, C.A. Cull, and V. Frighi Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group JAMA 281 21 1999 2005 2012
70. A.E. Butler, J. Janson, and S. Bonner-Weir Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes Diabetes 52 1 2003 102 110
71. C.E. Gleason, M. Gonzalez, and J.S. Harmon Determinants of glucose toxicity and its reversibility in the pancreatic islet beta-cell line, HIT-T15 Am J Physiol Endocrinol Metab 279 5 2000 E997 E1002
72. K. Kosaka, T. Kuzuya, and Y. Akanuma Increase in insulin response after treatment of overt maturity-onset diabetes is independent of the mode of treatment Diabetologia 18 1 1980 23 28
73. J.A. Scarlett, R.S. Gray, and J. Griffin Insulin treatment reverses the insulin resistance of type II diabetes mellitus Diabetes Care 5 4 1982 353 363
74. W.J. Andrews, B. Vasquez, and M. Nagulesparan Insulin therapy in obese, non-insulin-dependent diabetes induces improvements in insulin action and secretion that are maintained for two weeks after insulin withdrawal Diabetes 33 7 1984 634 642
75. W.T. Garvey, J.M. Olefsky, and J. Griffin The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus Diabetes 34 3 1985 222 234
76. T. Pratipanawatr, K. Cusi, and P. Ngo Normalization of plasma glucose concentration by insulin therapy improves insulin-stimulated glycogen synthesis in type 2 diabetes Diabetes 51 2 2002 462 468
77. H. Ilkova, B. Glaser, and A. Tunckale Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment Diabetes Care 20 9 1997 1353 1356
78. S. Park, and S.B. Choi Induction of long-term normoglycemia without medication in Korean type 2 diabetes patients after continuous subcutaneous insulin infusion therapy Diabetes Metab Res Rev 19 2 2003 124 130
79. E.A. Ryan, S. Imes, and C. Wallace Short-term intensive insulin therapy in newly diagnosed type 2 diabetes Diabetes Care 27 5 2004 1028 1032
80. M. Alvarsson, G. Sundkvist, and I. Lager Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients Diabetes Care 26 8 2003 2231 2237
81. S.E. Inzucchi Oral antihyperglycemic therapy for type 2 diabetes: scientific review JAMA 287 3 2002 360 372
82. J. Rosenstock Insulin therapy: optimizing control in type 1 and type 2 diabetes Clin Cornerstone 4 2 2001 50 64
83. J. Rosenstock, and M.C. Riddle Insulin therapy in type 2 diabetes. The CADRE handbook of diabetes management 2004 Medical Information Press New York
84. American Diabetes Association Standards of medical care for patients with diabetes mellitus Diabetes Care 27 S1 2004 S15 S35
85. H. Yki-Jarvinen, A. Dressler, and M. Ziemen Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group Diabetes Care 23 8 2000 1130 1136
86. J. Rosenstock, S.L. Schwartz, and C.M. Clark Jr. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin Diabetes Care 24 4 2001 631 636
87. J. Rosenstock, and K. Wyne Insulin treatment in type 2 diabetes B.J. Goldstein D. Muller-Wieland Textbook of type 2 diabetes 2003 Martin Dunitz London 131 154
88. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee Canadian Diabetes Association 2003 clinical practice guidelines for the prevention and management of diabetes in Canada Can J Diabetes 23 Supp 2 2003 S1 S152